Tumor antigen presentation via gp96-Ig platform

The "Tumor antigen presentation via gp96-Ig platform leading to activation of CD8+ cytotoxic T cells" refers not to a single molecule or receptor but rather an engineered immunotherapy approach that utilizes the heat shock protein gp96 fused with an immunoglobulin Fc domain ("gp96-Ig") as a vaccine adjuvant and delivery system. This platform works by secreting the gp96-Ig fusion protein from genetically modified cells, which binds and chaperones tumor-associated or pathogen-derived antigens. These complexes are efficiently taken up by professional antigen-presenting cells such as dendritic cells, which then process and present the antigens on MHC class I molecules—a process known as cross-presentation—thereby priming robust, polyclonal CD8+ cytotoxic T cell responses against tumors or infectious agents[1][2][5]. The approach has been tested in preclinical models for cancer and infectious diseases like malaria and COVID19. It is considered promising because it can induce tissue-resident memory CTLs at relevant sites such as the liver in malaria models, enhance long-term anti-tumor immunity, and be rapidly adapted for new pathogens. However, since this entry describes an entire therapeutic strategy/platform rather than a discrete molecular target like a receptor or enzyme, it does not fit standard definitions of "therapeutic target," making its use here technically incorrect[1][2]. If you need information about the actual molecular components involved—such as heat shock protein gp96 itself—or about canonical targets recognized by activated CD8+ T cells (e.g., specific tumor neoantigens), please specify further.

Other names

gp96-Ig vaccine platformHeat shock protein gp96-immunoglobulin fusionGp96-based antigen presentation system

Chaperoning tumor or pathogen antigens for cross-presentation on MHC class I molecules by antigen-presenting cells; Activation and expansion of antigen-specific CD8+ cytotoxic T lymphocytes.